RankAlpha logo
Back to Rankings

ANTX

AN2 TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case is that March financing extended runway into 2029, three Phase 2 programs are expected to be active in 2026, and the PV study offers the nearest company-controlled proof-of-concept catalyst with potential readouts beginning as early as 4Q26 [#IR-2026-03-17].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.3.
What can break
ATM usage or other equity issuance could pressure the stock despite improved runway [#8-K-2026-04-09].
Momentum
99
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.00 · Bull $7.50 · Bear $2.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $1.00
Why
Momentum99 · Δ7d +1.3
Value41 · Δ7d +0.1
Sentiment54 · Δ7d -3.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
34% active weight
Current posture
7d trendFlat
Δ7d
+1.3
Δ21d
-0.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
54
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
-31.8
Why this grade

Composite grade A. Momentum 99.2 / Value 41.1 / Sentiment 53.9

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$146.59M
Beta
-0.03
Shares Out
27.4M
P/E (TTM) · Derived
-3.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.39
Rev YoY
-
EPS YoY
+27.7%
Gross Margin
-
Op Margin
-
Net Debt
-$83.62M
Current Ratio
9.33
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology